Leponex

Clozapine, the active ingredient in Leponex, is an atypical antipsychotic presented as an oral tablet for oral use. It is indicated for patients with treatment‑resistant schizophrenia and schizoaffective disorder when other antipsychotics have not provided adequate control. The medication works by modulating dopamine and serotonin pathways, helping to reduce psychotic symptoms and improve overall functioning in affected individuals.

GNH USA supplies Leponex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Leponex (clozapine) is used within the antipsychotic therapeutic class to manage severe psychotic conditions.

- Treatment‑resistant schizophrenia: reduces positive and negative symptoms when other agents have failed. - Schizoaffective disorder: stabilises mood and psychotic features in combined presentations. - Maintenance therapy for chronic schizophrenia: helps maintain symptom control after initial stabilization.

Clozapine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Sedation or drowsiness. - Weight gain. - Excessive salivation (hypersalivation). - Constipation. - Dizziness or orthostatic light‑headedness. - Tachycardia.

Serious or Rare Side Effects: - Agranulocytosis (dangerously low white‑blood‑cell count). - Myocarditis or cardiomyopathy. - Seizures, especially at higher plasma levels. - Neuroleptic malignant syndrome. - Severe metabolic disturbances (hyperglycaemia, dyslipidaemia). - Life‑threatening hypotension.

Clozapine therapy requires careful monitoring and patient education. - Monitor blood counts: perform regular CBC with differential to detect agranulocytosis early. - Assess cardiac function: baseline ECG recommended because of myocarditis risk. - Evaluate metabolic parameters: monitor weight, glucose and lipid levels periodically. - Avoid abrupt discontinuation: taper under medical supervision to prevent withdrawal phenomena. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Clozapine interacts with several medicines that can alter its safety or effectiveness.

Major Interactions (Avoid): - Carbamazepine: may reduce clozapine levels and increase seizure risk. - Fluvoxamine: can markedly raise clozapine plasma concentrations. - Concurrent myelosuppressive agents: heighten risk of agranulocytosis.

Moderate Interactions (Monitor Closely): - Smoking (CYP1A2 induction): may lower clozapine levels; dose adjustment may be needed. - CYP1A2 inhibitors (e.g., ciprofloxacin): can increase clozapine concentrations. - QT‑prolonging drugs: monitor ECG for cardiac rhythm changes.